These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 7505147)

  • 1. Granulocyte colony-stimulating factor activating HIF-1alpha acts synergistically with erythropoietin to promote tissue plasticity.
    Liu SP; Lee SD; Lee HT; Liu DD; Wang HJ; Liu RS; Lin SZ; Su CY; Li H; Shyu WC
    PLoS One; 2010 Apr; 5(4):e10093. PubMed ID: 20404921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?
    Grossi A; Liumbruno GM
    Blood Transfus; 2008 Oct; 6(4):191-8. PubMed ID: 19112734
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.
    Tehranchi R
    Med Oncol; 2006; 23(1):37-49. PubMed ID: 16645228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).
    Valent P; Wimazal F; Schwarzinger I; Sperr WR; Geissler K
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):515-36. PubMed ID: 13677270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients with aplastic anemia and refractory anemia responding to combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin.
    Matsuda A; Kishimoto K; Yoshida K; Yagasaki F; Ito Y; Sakata T; Kawai N; Ino H; Hirashima K; Bessho M
    Int J Hematol; 2002 Oct; 76(3):244-50. PubMed ID: 12416735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategy for erythropoietin treatment in myelodysplastic syndromes.
    Hast R
    Med Oncol; 1999 Sep; 16(3):188-90. PubMed ID: 10523798
    [No Abstract]   [Full Text] [Related]  

  • 7. Hematopoietic growth factors and the treatment of tumor-associated anemias.
    Dührsen U; Hossfeld DK
    Ann Hematol; 1994 Nov; 69(5):213-21. PubMed ID: 7948310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes.
    Imamura M; Kobayashi M; Kobayashi S; Yoshida K; Mikuni C; Ishikawa Y; Matsumoto S; Sakamaki S; Niitsu Y; Hinoda Y
    Ann Hematol; 1994 Apr; 68(4):163-6. PubMed ID: 7516190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting use of growth factors in myelodysplastic syndromes.
    Newman K; Maness-Harris L; El-Hemaidi I; Akhtari M
    Asian Pac J Cancer Prev; 2012; 13(4):1081-91. PubMed ID: 22799286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of erythropoietin in the anemia of myelodysplastic syndrome.
    Stein RS
    Clin Lymphoma; 2003 Aug; 4 Suppl 1():S36-40. PubMed ID: 14556674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes.
    Hellström-Lindberg E; Birgegård G; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Merk K; Tangen JM; Winqvist I
    Leuk Lymphoma; 1993 Oct; 11(3-4):221-8. PubMed ID: 7505147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.
    Negrin RS; Stein R; Doherty K; Cornwell J; Vardiman J; Krantz S; Greenberg PL
    Blood; 1996 May; 87(10):4076-81. PubMed ID: 8639764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes.
    Bernell P; Stenke L; Wallvik J; Hippe E; Hast R
    Leuk Res; 1996 Aug; 20(8):693-9. PubMed ID: 8913323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
    Hellström-Lindberg E; Ahlgren T; Beguin Y; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Nilsson-Ehle H; Samuelsson J; Tangen JM; Winqvist I; Oberg G; Osterborg A; Ost A
    Blood; 1998 Jul; 92(1):68-75. PubMed ID: 9639501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.